A NEW FRONTIER
TARGETING IBD.

It’s estimated that more than half of patients living with inflammatory bowel disease (IBD) are unable to achieve and maintain disease remission, despite currently available therapies.1 Through our research and development efforts, we are committed to the relentless pursuit of novel therapies that break through the efficacy ceiling as we strive to improve the lives of patients living with IBD.

WE’RE FOCUSED ON INNOVATIVE TREATMENTS FOR THE FUTURE.

Gilead is studying multiple molecules for the treatment of IBD, with several clinical trials in both ulcerative colitis and Crohn’s disease.


Adapted from: 1. www.gilead.com/science-and-medicine/pipeline. Accessed May 4, 2020. 2. www.clinicaltrials.gov. Accessed May 4, 2020.

WE ACCELERATE
OUR DRUG DISCOVERIES.

We hire the best and the brightest. Then, we enhance our expansive internal expertise with select strategic partnerships and investments with external partners and collaborators to complement our in-house bench strength. This approach helps us transform the promise of science and technology into products that are truly innovative.

We are leveraging our global resources to take on IBD.
Gilead scientist in the lab

GILEAD & GALAPAGOS: OUR STRENGTHS COMBINED

  • In 2015, Gilead entered into a global partnership with Belgium-based biotech Galapagos.2 The partnership was further solidified in 2019 with a 10-year global research and development collaboration.3
  • Using Galapagos’ unique platform, we’re utilizing disease-related, human primary cell–based assays to discover and verify novel drug targets.
  • Together, we’re moving forward with a shared vision of transforming the treatment of inflammatory diseases.
Gilead scientists shaking hands

WE’RE LOOKING TO THE FUTURE

  • Our internal biomarker program is examining different therapies and identifying how they impact the disease course.
  • With the addition of different types of targeted pathway inhibitors, we hope to combine therapies that can be brought forward into future clinical studies to discover the most effective treatment for the individual, while potentially driving an even deeper response.
Multi-colored pills

LEVERAGING MICROBIOME SCIENCE TO ADVANCE DRUG DISCOVERY

  • In 2020, Gilead and Second Genome, a leader in microbiome science, entered into a multiyear collaboration aimed at combining the expertise of both companies to identify potential new targets and evaluate drug candidates for the treatment of IBD.
  • The collaboration also seeks to harness the latest insights in microbiome science to identify biomarkers related to the clinical response of investigational compounds.
  • Second Genome’s Microbiome Analytics Platform™ will allow for integrated analyses of microbiome data, including RNA and whole exosome sequencing, to identify biomarkers—microbial strains, products, and their host targets—for the development of novel drugs.4
Oncologists with his patient

ADVANCING IBD RESEARCH

  • Gilead is working together with the Crohn’s and Colitis Foundation (CCF) to advance IBD research. As a member of IBD Plexus®, the CCF’s research information exchange platform, Gilead is contributing to the analysis of high-definition, multi-omic data using biosamples collected from patients with IBD.
  • This will help identify predictors of response to IBD therapies as well as predictors of disease relapse among current treatment responders.
  • Results from these research efforts complement Gilead’s IBD development programs and further support our mission to develop medicines that break through the efficacy ceiling and improve the lives of patients living with IBD.5

BUILDING MOMENTUM: OUR HISTORY IN INFLAMMATION

2014
Gilead and ONO partner to evaluate Bruton’s tyrosine kinase (BTK) inhibitors for B-cell malignancies and inflammatory diseases6
2015
Gilead and Galapagos announce global collaboration to address inflammatory diseases2
2016
Gilead initiates Phase 3 studies of a Janus kinase 1 (JAK1) inhibitor for patients with rheumatoid arthritis, Crohn’s disease, and ulcerative colitis7
2017
Gilead initiates multiple Phase 2 studies of JAK1 pathway inhibition in additional inflammatory diseases8
2019
Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases3
2020
Gilead enters the microbiome space with Second Genome to identify biomarkers and potential new targets and drug candidates in IBD4
References

References: 1. Crohn’s and Colitis Foundation. https://www.crohnscolitisfoundation.org/sits/default/files/2019-02/Updated%20IBD%20Factbook.pdf. November, 2014. Accessed June 8, 2020. 2. Data on file. Gilead Sciences, Inc.; 2015. 3. Data on file. Gilead Sciences, Inc.; 2019. 4. Data on file. Gilead Sciences, Inc.; 2020. 5. Crohn’s and Colitis Foundation. https://www.crohnscolitisfoundation.org/research/current-research-initiatives/ibd-plexus. Accessed May 14, 2020. 6. Data on file. Gilead Sciences, Inc.; 2014. 7. Data on file. Gilead Sciences, Inc.; 2016. 8. Data on file. Gilead Sciences, Inc.; 2017.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5968 10/20